How well does Vabysmo(Faricimab-svoa) work?

Clinical studies demonstrated non-inferiority to aflibercept in improving visual acuity for indicated conditions.

Treatment Outcomes

In nAMD studies, VABYSMO showed non-inferior visual acuity improvements compared to aflibercept over 48 weeks. For DME, both fixed and variable dosing regimens achieved similar BCVA gains at year 1 and 2. In RVO trials, week 24 results confirmed non-inferiority to aflibercept. Treatment effects were consistent across subgroups including age, gender, and baseline visual acuity.